All News

Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.

Experts provide guidance on managing high cholesterol in adults older than 75 years, emphasizing personalized care and shared decision-making for optimal outcomes.

At Baptist Health South Florida, pharmacists are embedded in all areas of cardiovascular care, an expert said.

A panel of health care experts at Asembia’s AXS25 Summit discussed the critical need for improved patient education and resources to help navigate complex financial assistance programs and health care plans.

The Inflation Reduction Act of 2022 (IRA) drug negotiation provisions will fundamentally reshape Medicare drug pricing, provider reimbursement, and health care delivery dynamics across Part B and commercial markets, according to panelists at Asembia’s AXS25 Summit.

Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.

Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.

Explore the role of JAK inhibitors in myelofibrosis treatment, focusing on optimizing dosages and managing adverse effects for better patient outcomes.

Specialty pharmacies can leverage advanced analytics, AI, and comprehensive data insights to create targeted clinical programs.

A phase 1b study demonstrated that continuous subcutaneous infusion of low-dose lenalidomide in patients with relapsed or refractory (R/R) multiple myeloma achieved promising efficacy with significantly reduced hematologic toxicity compared to conventional oral dosing.

Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.

Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.

How would you counsel these patients?

Nipocalimab the first and only FcRn blocker approved in anti-acetylcholine receptor– or anti-muscle-specific kinase adults and children with generalized myasthenia gravis.

Pharmacists can perform MTM consultations and provide clinical recommendations to the health care team.

Artificial intelligence (AI) models enhance cancer cachexia detection, improving accuracy in predicting muscle atrophy and patient outcomes through advanced biomarker analysis.

As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models.

At Asembia’s AXS25 Summit, Shea Hudson spotlighted how pharmacists are transforming into essential clinical partners through advanced technology, patient advocacy, and value-based collaboration.

Explore the latest advancements in chronic lymphocytic leukemia treatment, focusing on BTK and BCL2 inhibitors, monoclonal antibodies, and patient management strategies.

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.

A novel orally bioavailable RIPTAC therapeutic targeting the p53-Y220C mutation demonstrates selective cancer cell killing by inducing proximity between mutant p53 and an essential protein, offering a promising new strategy for treating historically untreatable tumors.

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

Rising costs of these therapies challenge affordability and access.

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.

A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.

The phase 2 ROME trial demonstrated that combining tissue and liquid biopsies to guide tailored therapy in advanced solid tumors significantly improves survival outcomes compared to standard of care or single-biopsy approaches, highlighting the value of dual profiling in precision oncology.